Evidence map›Paper›PMID 30467770›Full record

SynthesisMetabolic brain disease2019

Alpha-lipoic acid in the treatment of psychiatric and neurological disorders: a systematic review.

Caren Nádia Soares de Sousa, Cláudio Manuel Gonçalves da Silva Leite, Ingridy da Silva Medeiros, Luna Costa Vasconcelos, Lucas Moraes Cabral, Cláudio Felipe Vasconcelos Patrocínio, Marianna Letícia Vasconcelos Patrocínio, Fayçal Mouaffak, Oussama Kebir, Danielle Macedo and 2 more

Abstract readSystematic Review
PubMed Publisher
In one paragraph

Synthesis in Metabolic brain disease, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 2 pooled it
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 40 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Oxidative stress and inflammatory process in borderline personality disorder (BPD): a narrative review.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2023
    Review
  13. VANL-100 Attenuates Beta-Amyloid-Induced Toxicity in SH-SY5Y Cells.International journal of molecular sciences · 2022
    Article
  14. Article
  15. Review
  16. Targeting Mitochondrial Dysfunction for Bipolar Disorder.Current topics in behavioral neurosciences · 2021
    Review
  17. Review
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 2 countries.

Caren Nádia Soares de SousaNeuropsychopharmacology Laboratory, Drug Research and Development Center, Department of Physiology and Pharmacology, Faculty of Medicine, Federal University of Ceará, Coronel Nunes de Melo Street, 1127, Fortaleza, CE, 60431-270, Brazil.
Cláudio Manuel Gonçalves da Silva LeiteNeuropsychopharmacology Laboratory, Drug Research and Development Center, Department of Physiology and Pharmacology, Faculty of Medicine, Federal University of Ceará, Coronel Nunes de Melo Street, 1127, Fortaleza, CE, 60431-270, Brazil.
Ingridy da Silva MedeirosNeuropsychopharmacology Laboratory, Drug Research and Development Center, Department of Physiology and Pharmacology, Faculty of Medicine, Federal University of Ceará, Coronel Nunes de Melo Street, 1127, Fortaleza, CE, 60431-270, Brazil.
Luna Costa VasconcelosNeuropsychopharmacology Laboratory, Drug Research and Development Center, Department of Physiology and Pharmacology, Faculty of Medicine, Federal University of Ceará, Coronel Nunes de Melo Street, 1127, Fortaleza, CE, 60431-270, Brazil.
Lucas Moraes CabralNeuropsychopharmacology Laboratory, Drug Research and Development Center, Department of Physiology and Pharmacology, Faculty of Medicine, Federal University of Ceará, Coronel Nunes de Melo Street, 1127, Fortaleza, CE, 60431-270, Brazil.
Cláudio Felipe Vasconcelos PatrocínioSchool of Medicine, University Center Christus-Unichristus, Fortaleza, Ceará, Brazil.
Marianna Letícia Vasconcelos PatrocínioSchool of Medicine, University Center Christus-Unichristus, Fortaleza, Ceará, Brazil.
Fayçal MouaffakDepartment of Seine Saint Denis, Ville Evrard Psychiatric Hospital, Paris, France.
Oussama KebirLaboratory of Pathophysiology of Psychiatric Diseases, Center for Psychiatry and Neurosciences, INSERM U894, University Paris Descartes, Paris, France.
Danielle MacedoNeuropsychopharmacology Laboratory, Drug Research and Development Center, Department of Physiology and Pharmacology, Faculty of Medicine, Federal University of Ceará, Coronel Nunes de Melo Street, 1127, Fortaleza, CE, 60431-270, Brazil.
Manoel Cláudio Azevedo PatrocínioSchool of Medicine, University Center Christus-Unichristus, Fortaleza, Ceará, Brazil.
Silvânia Maria Mendes VasconcelosNeuropsychopharmacology Laboratory, Drug Research and Development Center, Department of Physiology and Pharmacology, Faculty of Medicine, Federal University of Ceará, Coronel Nunes de Melo Street, 1127, Fortaleza, CE, 60431-270, Brazil. silvania_vasconcelos@yahoo.com.br.
Universidade Federal do Ceará · BRHospital Geral de Fortaleza · BRHôpital de Ville-Évrard · FRInstitut de Psychiatrie et Neurosciences de Paris · FRUnichristus · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite the existence of many preclinical studies, scientific evidence is lacking on the clinical use of alpha-lipoic acid (ALA) for central nervous system disorders. Therefore, we aimed at revising the literature concerning the use of ALA for the treatment of psychiatric and neurological conditions and to point out what is missing for the introduction of this antioxidant to this purpose. For this systematic review we performed a search using PubMed and SCOPUS databases with the following keywords: "alpha-Lipoic Acid AND central nervous system OR psychiatric disorders OR neurological disorders OR mood disorders OR anxiety OR psychosis OR Alzheimer OR Parkinson OR stroke". The total number of references found after automatically and manually excluding duplicates was 1061. After primary and secondary screening 32 articles were selected. Regarding psychiatric disorders, the studies of ALA in schizophrenia are advanced being ALA administration related to the improvement of schizophrenia symptoms and side effects of antipsychotic medication. In neurological disorders, ALA as a supplement was effective in the prevention of Alzheimer disease progression. For stroke, the use of the supplement ALAnerv® (containing 300 mg ALA) presented important results, since it was observed a reversal of clinical parameters and oxidative imbalance in these patients. For other neurological conditions, such as encephalopathy, multiple sclerosis, traumatic brain injury, mitochondrial disorders and migraine, the results are still preliminary. Overall, there is a need of well-designed clinical trials to enhance the clinical evidences of ALA effects for the treatment of neurological and psychiatric conditions.

Indexed as

HumansMental DisordersNervous System DiseasesThioctic AcidTreatment OutcomeThioctic AcidAlpha-lipoic acidCentral nervous systemNeurological disordersPsychiatric disorders

Identifiers

PMID30467770
OpenAlexW2901001082

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.